title: Aging biology and novel targets for drug discovery.
abstract: Despite remarkable technological advances in genetics and drug screening, the discovery of new pharmacotherapies has slowed and new approaches to drug development are needed. Research into the biology of aging is generating many novel targets for drug development that may delay all age-related diseases and be used long term by the entire population. Drugs that successfully delay the aging process will clearly become "blockbusters." To date, the most promising leads have come from studies of the cellular pathways mediating the longevity effects of caloric restriction (CR), particularly target of rapamycin and the sirtuins. Similar research into pathways governing other hormetic responses that influence aging is likely to yield even more targets. As aging becomes a more attractive target for drug development, there will be increasing demand to develop biomarkers of aging as surrogate outcomes for the testing of the effects of new agents on the aging process.
authors.affiliation: Centre for Education and Research on Ageing, Concord RG Hospital, Hospital Road, Concord, NSW 2139, Australia. dlecouteur@med.usyd.edu.au
authors.forename: David G
authors.initials: DG
authors.lastname: Le Couteur
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: McLachlan
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Quinn
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Simpson
authors.forename: Rafael
authors.initials: R
authors.lastname: de Cabo
mesh_terms: D000375:Aging / Q000502:physiology*; D055808:Drug Discovery / Q000458:organization & administration*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D008136:Longevity / Q000187:drug effects*